Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer

Published:2005-05-03 Issue:4 Volume:56 Page:361-369
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Bruno Rene,Washington Carla B.,Lu Jian-Feng,Lieberman Grazyna,Banken Ludger,Klein Pamela

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-005-1026-z.pdf

Reference20 articles.

1. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L et al (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737–744

2. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D et al (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659–2671

3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al (1999) Multinational study of the efficacy and safety of humanized monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648

4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

5. 2003 Herceptin Package Insert

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients;Cancer Chemotherapy and Pharmacology;2024-08-23

2. Impact of Resistance on Therapeutic Design: A Moran Model of Cancer Growth;Bulletin of Mathematical Biology;2024-03-19

3. Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer;Expert Opinion on Drug Metabolism & Toxicology;2024-01-12

4. Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors;Clinical Cancer Research;2023-12-13

5. No Interference of H9 Extract on Trastuzumab Pharmacokinetics in Their Combinations;International Journal of Molecular Sciences;2023-11-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3